JP2020537526A5 - - Google Patents

Download PDF

Info

Publication number
JP2020537526A5
JP2020537526A5 JP2020521363A JP2020521363A JP2020537526A5 JP 2020537526 A5 JP2020537526 A5 JP 2020537526A5 JP 2020521363 A JP2020521363 A JP 2020521363A JP 2020521363 A JP2020521363 A JP 2020521363A JP 2020537526 A5 JP2020537526 A5 JP 2020537526A5
Authority
JP
Japan
Prior art keywords
adenovirus vector
expression cassette
vector according
region
adenovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020521363A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020537526A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/078212 external-priority patent/WO2019076882A1/en
Publication of JP2020537526A publication Critical patent/JP2020537526A/ja
Publication of JP2020537526A5 publication Critical patent/JP2020537526A5/ja
Withdrawn legal-status Critical Current

Links

JP2020521363A 2017-10-16 2018-10-16 Rsv抗原性タンパク質又はその断片をコードする2つの発現カセットを有するアデノウイルスベクター Withdrawn JP2020537526A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762572951P 2017-10-16 2017-10-16
US62/572,951 2017-10-16
PCT/EP2018/078212 WO2019076882A1 (en) 2017-10-16 2018-10-16 ADENOVIRAL VECTORS COMPRISING TWO EXPRESSION CASSETTES ENCODING RSV ANTIGENIC PROTEINS OR FRAGMENTS THEREOF

Publications (2)

Publication Number Publication Date
JP2020537526A JP2020537526A (ja) 2020-12-24
JP2020537526A5 true JP2020537526A5 (enExample) 2021-11-25

Family

ID=63896162

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020521363A Withdrawn JP2020537526A (ja) 2017-10-16 2018-10-16 Rsv抗原性タンパク質又はその断片をコードする2つの発現カセットを有するアデノウイルスベクター

Country Status (8)

Country Link
US (1) US11859199B2 (enExample)
EP (1) EP3697919A1 (enExample)
JP (1) JP2020537526A (enExample)
CN (1) CN111527213A (enExample)
BR (1) BR112020007008A2 (enExample)
CA (1) CA3079048A1 (enExample)
MX (1) MX2020003748A (enExample)
WO (1) WO2019076882A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022007774A1 (zh) * 2020-07-06 2022-01-13 嘉兴安宇生物科技有限公司 一种新型黑猩猩腺病毒载体及其构建方法和应用
WO2022102894A1 (ko) * 2020-11-10 2022-05-19 주식회사 바이오리더스 코로나바이러스의 스파이크 단백질 및 뉴클레오캡시드 단백질을 동시발현하는 복제불능 아데노바이러스를 이용한 코로나바이러스 백신
KR102399308B1 (ko) * 2020-11-10 2022-05-20 주식회사 비엘 코로나바이러스의 스파이크 단백질 및 뉴클레오캡시드 단백질을 동시발현하는 복제불능 아데노바이러스를 이용한 코로나바이러스 백신
KR102882279B1 (ko) * 2022-05-09 2025-11-10 주식회사 모아라이프플러스 코로나바이러스의 스파이크 단백질, 뉴클레오캡시드 단백질 및 PgsA 단백질을 동시발현하는 복제불능 아데노바이러스를 이용한 코로나바이러스 백신

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005015728A1 (de) 2005-04-06 2006-10-12 Robert Bosch Gmbh Verbindungsvorrichtung für einen Antrieb sowie Verfahren zur Herstellung einer Verbindungsvorrichtung
WO2008095027A2 (en) * 2007-01-30 2008-08-07 Cedars-Sinai Medical Center Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
EP2181121A4 (en) 2007-03-21 2012-07-11 Id Biomedical Corp Quebec CHIMÄRE ANTIGENE
HUE039908T2 (hu) 2009-02-02 2019-02-28 Glaxosmithkline Biologicals Sa Majom adenovírusból származó nukleinsav- és aminosav-szekvenciák, azt tartalmazó vektorok és alkalmazásuk
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
WO2012089231A1 (en) 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
JP6091435B2 (ja) 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス(aav)ベクターを用いたタンパク質の送達
WO2014078446A2 (en) 2012-11-16 2014-05-22 Allergan, Inc. Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations
EP3154576A1 (en) * 2014-06-13 2017-04-19 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
WO2016198621A1 (en) 2015-06-12 2016-12-15 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
GB201513176D0 (en) 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response

Similar Documents

Publication Publication Date Title
Das et al. Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review
Mezhenskaya et al. M2e-based universal influenza vaccines: a historical overview and new approaches to development
Dheerasekara et al. Hantavirus infections—treatment and prevention
JP2017515508A5 (enExample)
JP2008530245A5 (enExample)
JP2016513115A5 (enExample)
JP2020528911A5 (enExample)
JP2013506672A5 (enExample)
JP2017502662A5 (enExample)
JP2015533376A5 (enExample)
CA2764903C (en) Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens
WO2022135563A1 (zh) 同时诱导抗多种病毒的免疫应答的方法
JP2021500880A5 (enExample)
US11859199B2 (en) Adenoviral vectors with two expression cassettes encoding RSV antigenic proteins or fragments thereof
ES3056141T3 (en) Simian adenoviral vectors with two expression cassettes
JP2012517239A5 (enExample)
JP4797149B2 (ja) インフルエンザウイルスに対するベクターワクチン
JP2025504364A (ja) 慢性b型肝炎感染症を処置または防止するための複数抗原治療ワクチン
Kim et al. Preparedness for Future Pandemics Using a Highly Effective Recombinant Vesicular Stomatitis Virus-Based Vaccine Platform Technology: Strategies for Developing Superior Vaccines. Medical Research Archives,[online] 13 (12)
Lee et al. Journal of Yeungnam Medical Science
pertussis Novavax et al. Covid-19 Vaccines: Several technologies at work
JP2025506732A (ja) 感染症およびがんの免疫療法適用のための多用途のウイルス様小胞(vlv)プラットフォーム
Sallberg et al. 714. Attenuation of V-or C-Defective Measles Viruses: Infection Control by the Inflammatory and Interferon Responses of Rhesus Monkeys
CN111328344A (zh) 增强的启动子